• Oxurion NV reports first patient dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Tuesday September 1st 2020

  • Precigen ActoBio announces positive topline results from Phase 1b study of AG019 ActoBiotics

    Tuesday August 11th 2020

  • Mithra announces shelf life extension for Myring™ to 36 months

    Tuesday August 4th 2020

  • Gilead en Galapagos kondigen positieve Europese CHMP opinie aan voor Jyseleca® (Filgotinib) voor de behandeling van volwassenen met matige tot ernstige reumatoïde artritis

    Friday July 24th 2020

  • Aligos Therapeutics and KU Leuven announce collaboration for the development of a therapeutic candidate targeting Coronavirus

    Thursday July 2nd 2020

  • US multicenter study shows Idylla™ allows rapid and accurate mutation testing results across different laboratory settings

    Friday June 26th 2020

  • eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept

    Wednesday June 17th 2020

  • Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate

    Thursday June 11th 2020

  • Your news here?

  • New analyses of Phase 2 Equator Clinical Program support durable efficacy of Filgotinib in Psoriatic Arthritis

    Monday June 8th 2020

  • Filgotinib demonstrates durable efficacy and consistent safety profile at 52 weeks in Finch 1 and 3 studies in rheumatoid arthritis

    Thursday June 4th 2020

  • Celyad provides update on allogeneic CAR-T franchise

    Tuesday June 2nd 2020


Strategic Partners